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I measured total creatine kinase (CK; EC 2.7.3.2) activity and isoenzyme pattern in normal and neoplastic tissues. CK activity was detected in all of them examined. in various tumors it was greater than, less than, or the same as that in normal tissue, no clear correlation being seen between total activity and growth rate or degree of differentiation. In several cases, there was a greater proportion of the CK-MM isoenzyme, and 15 of 53 cases showed an atypical CK-MM band. The atypical CK-MM band, also reported by others, might be an insensitive and nonspecific tumor marker. The CK-BB isoenzyme, ubiquitous in neoplastic tissues, might accordingly be a nonspecific marker. Total CK activity was very low in most tumor tissues. Presumably a bulky tumor or an advanced stage of malignancy is a requisite to release of routinely detectable CK-BB into the circulation. Hoag and Amies (4) reported CK-BB isoenzyme in serum of a patient with prostatic carcinoma and in tissue homogenates. A full understanding of the pathobiochemical mechanism underlying increased concentrations of CK-MB or CK-BB in blood and an optimal clinical use of assays for these isoenzymes require knowledge of their concentration in tissues. As part of a continuing study on CK activity and its isoenzyme pattern in normal and neoplastic tissue from the gastrointestinal (GI) tract (5), I explored the activity and isoenzyme composition of CK in a series of other normal and neoplastic tissues.
Materials and Methods
Surgical specimens
from 34 women and 19 men (17 to 84 years old, median age 65) who were undergoing surgery for benign and malignant tumors were sent to the histology laboratory without delay. Portions of tumor tissue-and of the corresponding normal tissue, if available-were obmined for CK assays. The remaining specimens were fixed in formalin for histological examination.
To evaluate the reproducibility of the tissue-preparation procedure, I cut a solid ovarian tumor into 15 pieces of almost identical size, which I homogenized the same day.
Tissue homogenates were prepared as described previously (6) . CK activity was estimated at 37 #{176}C with an HMA spectrophotometer (Hycel Inc., Houston, TX 77036) by the kinetic method of Rosalki (7) , with use of kits from Calbiochem, La Jolla, CA 92037. If only CK-BB was found, no further quantitative study was carried out. If bands other than CK-BB were identified, the percentage distribution of each isoenzyme was determined by column chromatography as described by Yasmineh and Hanson (8) . Each fraction eluted was assayed for CK activity with an HMA spectrophotometer.
The measured total CK activity of supernates and of the eluate were corrected for sample-blank activity, as measured with creatine phosphate omitted from the CK incubation mixture.
Results
Reproducibility
I evaluated column reproducibility
by repeated analysis of a serum pool fortified with MB and BB isoenzymes from an extract of heart and intestinal
tissues.
The results are summarized in Table 1 . The total CK concentration (U/g wet wt.) in 15 samples from the same solid ovarian tumor varied by a mean of 7%.
CK Activity and Its lsoenzyme Composition in Normal Tissue
As Table 2 shows, CK was present in all the normal tissue assayed, activity being greatest in tissue from the GI tract and urinary bladder; somewhat lower for kidney; still lower for lung, ovary, liver, and thyroid gland; and lowest for breast tissue. The BB isoenzyme was the exclusive or predominant form in kidney, lung, ovary, thyroid gland, stomach, breast tissue, urinary bladder, and colon. The MM form was predominant in liver, with lesser activity of the BB fraction, and trace activity of the MB isoenzyme. Trace activity of the MB isoenzyme was found in one specimen Table 2 The isoenzyme pattern varied considerably in 10 ovarian tumors. Epithelial malignant tumors contained predominantly CK-BB isoenzyme. In contrast, granulosa-cell tumor and malignant lymphoma contained predominantly CK-MM fraction. The only case of mixed germ-cell tumor contained exclusively CK-BB isoenzyme, whereas a pure dysgerminoma contained predominantly CK-BB form. The isoenzyme pattern of breast tumors also varied greatly (0 to 100% for CK-MM and CK-BB). Possibly CK-BB is also converted to CK-MM in this group of tumors.
Normal lymph node was not available for study, but neoplastic tissue at such sites varied greatly in its isoenzyme distribution.
The isoenzyme pattern of thyroid papillary carcinoma was identical to that of normal tissue. However, the thyroid follicular adenoma that I examined contained exclusively CK-BB isoenzyme. In cholangiolarcell carcinoma, the CK isoenzyme pattern for the neoplastic tissue demonstrated a decrease in CK-BB with slight increase in CK-MM as compared with its homologous nonneoplastic tissue. Normal brain tissue was not available for study, but it is known to contain exclusively CK-BB isoenzyme (9). In the case of glioblastoma multiforme, the tissue contained twice as much CK-MM as CK-BB isoenzyme. A meningioma had similar isoenzyme distribution, but low total CK activity. In the case of liposarcoma, the isoenzyme distribution was the reverse of that in a lipoma. The isoenzyme pattern of normal fat tissue is probably similar to that of lipoma.
Discussion
Few quantitative data were available for comparison with my results for either normal or neoplastic tissues. In the data I previously reported (10), CK activity might have been overestimated, because no correction was made for adenylate kinase activity. Those commercial reagents that generally follow Oliver's recommendation include 10 mmol of AMP per liter in the assay system to inhibit adenylate kinase (11). Although this is no doubt satisfactory for tissue that is relatively high in CK activity, I found that inhibition was incomplete when adenylate kinase activity was relatively high, as in skeletal or cardiac muscle. It is difficult to compare tissue CK activity per gram of wet tissue with other studies in the literature because the assay conditions and the procedures for tissue preparation are so different. The isoenzyme distribution I found for normal tissue differs from data by Urdal et al. (12) , who claimed that CK-BB was the only cytoplasmic CK isoenzyme present in most tissues they examined. However, I found that a substantial proportion of activity in liver, kidney, lung, and thyroid gland was inhibited by anti-M, confirming that those bands were indeed CK-MM rather than mitochondrial CK. There was no clear relationship between the activity and tumor growth rate or degree of differentiation. In a previous study (5) , atypical or mitochondrial CK-MM was found in one GI tumor-tissue homogenate. In this study, the mitochondrial CK-MM, which was not inhibited by anti-M, was found in 15 cases of various tumors. CK isoenzymes were not assayed on those 15 patients' sera. The incidence of atypical CK-MM band in sera was low (14, 15). The vast majority of the reported cases of atypical CK-MM have been found in patients with malignant tumors (15-18). It was also reported in patients with other conditions, such as shock (19) . Therefore, atypical CK-MM could be a nonspecific and insensitive tumor marker.
The CK-BB isoenzyme, ubiquitous in neoplastic tissues, might accordingly be a nonspecific tumor marker. Total CK activity was very low in some tumors, for example, squamous cell carcinoma of the lung and three cases of hypernephroma. It is unlikely that one will find increased concentrations of CK-BB in serum in these types of tumors, whereas CK activity was relatively high in some adenocarcinomas of lung and in duct-cell carcinoma of the breast. CK-BB isoenzyme merits further investigation as a tumorassociated marker for patients with these types of malignant tumors. Although it would not be specific for a particular tumor, evaluation of BB isoenzyme in serum might indicate the extent of disease or the response to therapy. High concentrations of the BB isoenzyme in serum have been reported in patients with cancers of the breast, stomach, and prostate gland (20-22). Presumably a bulky tumor or an advanced stage of malignancy is required to release enough CK-BB into the circulation to be detectable by the routine methods for CK-BB isoenzyme.
Shatton et al. (23) found that when the BB form was the only isoenzyme in a tissue, the corresponding experimental tumor expressed MM as well as BB activity. In my study, conversion of CK-BB to CK-MM was found in several cases. This finding that some isoenzyme composition may deviate toward the differentiated form is analogous to the well-known ectopic production of polypeptide hormones by many human tumors of non-endocrine organs (24) , where genes also are expressed for proteins required for differentiated functions of tissue other than the tissue of origin. Thus, in the misprogramming of protein synthesis in some tumors, the organ site specificity as well as temporal specificity of gene expression can be breached for enzymes as well as hormones.
